A detailed history of Credit Suisse Ag transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 36,383 shares of DYN stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,383
Previous 26,858 35.46%
Holding current value
$1.09 Million
Previous $357,000 189.08%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$13.06 - $29.18 $124,396 - $277,939
9,525 Added 35.46%
36,383 $1.03 Million
Q4 2023

Feb 08, 2024

SELL
$6.62 - $13.64 $6,401 - $13,189
-967 Reduced 3.48%
26,858 $357,000
Q3 2023

Nov 13, 2023

SELL
$8.6 - $12.18 $50,069 - $70,911
-5,822 Reduced 17.3%
27,825 $249,000
Q2 2023

Aug 11, 2023

BUY
$8.53 - $14.28 $84,711 - $141,814
9,931 Added 41.87%
33,647 $378,000
Q1 2023

May 10, 2023

BUY
$10.88 - $15.0 $57,914 - $79,845
5,323 Added 28.94%
23,716 $273,000
Q4 2022

Feb 13, 2023

BUY
$9.37 - $13.8 $2,164 - $3,187
231 Added 1.27%
18,393 $213,000
Q3 2022

Nov 10, 2022

BUY
$7.2 - $15.17 $1,058 - $2,229
147 Added 0.82%
18,162 $231,000
Q2 2022

Aug 12, 2022

BUY
$4.36 - $10.5 $7,538 - $18,154
1,729 Added 10.62%
18,015 $124,000
Q1 2022

May 16, 2022

SELL
$6.52 - $12.27 $5,985 - $11,263
-918 Reduced 5.34%
16,286 $156,000
Q4 2021

Feb 14, 2022

BUY
$11.89 - $16.07 $35,931 - $48,563
3,022 Added 21.31%
17,204 $204,000
Q3 2021

Nov 12, 2021

BUY
$15.6 - $21.46 $49,545 - $68,156
3,176 Added 28.86%
14,182 $230,000
Q2 2021

Aug 16, 2021

SELL
$15.94 - $22.33 $1.37 Million - $1.91 Million
-85,711 Reduced 88.62%
11,006 $231,000
Q1 2021

May 14, 2021

BUY
$14.0 - $29.3 $833,280 - $1.74 Million
59,520 Added 160.01%
96,717 $1.5 Million
Q4 2020

Feb 12, 2021

BUY
$16.81 - $23.94 $333,594 - $475,089
19,845 Added 114.37%
37,197 $781,000
Q3 2020

Nov 13, 2020

BUY
$20.0 - $23.9 $347,040 - $414,712
17,352 New
17,352 $350,000

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.55B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.